Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study
Chen Yang Kevin Zhang, Rayoun Ramendra, Meghan Aversa, Rasheed Ghany, Jussi Tikkanen, Ella Huszti, Jonathan Yeung, Shaf Keshavjee, Lianne G Singer, Tereza Martinu · 2026
Read Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study by Chen Yang Kevin Zhang, Rayoun Ramendra, Meghan Aversa, Rasheed Ghany, Jussi Tikkanen, Ella Huszti, Jonathan Yeung, Shaf Keshavjee, Lianne G Singer, Tereza Martinu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13670396.txt.
Description
Chen Yang Kevin Zhang and colleagues tracked acid-blocking drugs in lung transplant patients over twenty years. Reflux threatens transplanted lungs, so proton pump inhibitors became routine after surgery. At their center, nearly nine in ten of 1,308 recipients took them long-term, and use topped ninety percent after 2007.
Yet patients on the drugs fared no better than those off them. Time to chronic lung damage, death, or a second transplant looked the same. Doubling the dose changed nothing either. The authors question whether near-universal use is justified, while calling for trials to settle the question.
Catalog record
| CREATOR | Chen Yang Kevin Zhang, Rayoun Ramendra, Meghan Aversa, Rasheed Ghany, Jussi Tikkanen, Ella Huszti, Jonathan Yeung, Shaf Keshavjee, Lianne G Singer, Tereza Martinu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |